ALLERGY THERAPEUTICS PLC

Board/Management Information • Oct 8, 2014

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 7390T

Allergy Therapeutics PLC

08 October 2014

8 October 2014

Allergy Therapeutics plc

("Allergy Therapeutics" or the "Company")

Directorate Change

Allergy Therapeutics plc (AIM: AGY), the fully integrated speciality pharmaceutical company specialising in allergy vaccines, announces that Alejandro Esteban Weinstein Manieu has stepped down from the Board with immediate effect.

Peter Jensen, Chairman of the Board, said: "Alejandro has made an enormous contribution to the development of Allergy Therapeutics since his involvement in 2009 and I would like to take this opportunity to thank him for his valuable guidance and support."

For further information

Allergy Therapeutics	+44 (0) 1903 845 820
Manuel Llobet, Chief Executive Officer Ian Postlethwaite, Finance Director
Peel Hunt LLP	+44 (0) 20 7418 8900
James Steel Clare Terlouw
FTI Consulting	+44 (0) 20 3727 1000
Simon Conway Victoria Foster Mitchell

Notes to editors

About Allergy Therapeutics

Allergy Therapeutics is a specialty pharmaceutical company focused on allergy vaccination. It has a growing business achieving revenue in the last financial year of £42 million mainly in Europe through its own sales and marketing infrastructure and further afield through distributors. The Company is expanding its infrastructure into the Emerging Markets

This information is provided by RNS

The company news service from the London Stock Exchange

END

BOAUGGWCUUPCUQR